AIM: To identify an appropriate therapeutic regimen for using aconite cake-separated moxibustion to treat diarrhea-predominant irritable bowel syndrome(D-IBS).METHODS: A factorial design was employed to examine the tw...AIM: To identify an appropriate therapeutic regimen for using aconite cake-separated moxibustion to treat diarrhea-predominant irritable bowel syndrome(D-IBS).METHODS: A factorial design was employed to examine the two factors of moxibustion frequency and number of cones. The two tested frequencies were three or six moxibustion sessions per week, and the two tested doses were one or two cones per treatment. A total of 166 D-IBS patients were randomly divided into four treatment groups, which included each combination of the examined frequencies and doses. The bilateral Tianshu acupoints(ST25) and the Qihai acupoint(RN6) were selected for aconite cake-separated moxibustion. Each patient received two courses of treatment, and each course had a duration of 2 wk. For each group, the scores on the Birmingham irritable bowel syndrome(IBS) symptom questionnaire, the IBS Quality of Life scale, the Self-Rating Depression Scale(SDS), the Self-Rating Anxiety Scale(SAS), the Hamilton Depression(HAMD) scale, and the Hamilton Anxiety(HAMA) scale were determined before treatment, after the first course of treatment, and after the second course of treatment. RESULTS: The symptom, quality of life, SDS, SAS, HAMD, and HAMA scores of the patients in all 4 aconite cake-separated moxibustion groups were significantly lower after the first and second courses of treatment than before treatment(P < 0.001 for all). The symptom, quality of life, SDS, SAS, HAMD, and HAMA scores of the patients in all four aconite cake-separated moxibustion groups were significantly lower after the second course of treatment than after the first course of treatment(P < 0.001 for all). Between-group comparisons after the second course of treatment revealed that the symptom scores for group 1(1 cone, 3 treatments/wk) and group 3(2 cones, 3 treatments/wk) were significantly lower than that for group 2(1 cone, 6 treatments/wk)(5.55 ± 5.05 vs 10.45 ± 6.61, P < 0.001; 5.65 ± 4.00 vs 10.45 ± 6.61, P < 0.001). Regarding the two levels of the two examined factors for aconite cake-separated moxibustion, after the first course of treatment, the changes in HAMA scores weresignificantly different for the two tested moxibustion frequencies(P = 0.011), with greater changes for the "6 treatments/wk" groups than for the "3 treatments/wk" groups; in addition, there were interaction effects between the number of cones and moxibustion frequency(P = 0.028). After the second course of treatment, changes in symptom scores for the 2 tested moxibustion frequencies were significantly different(P = 0.002), with greater changes for the "3 treatments/wk" groups than for the "6 treatments/wk" groups.CONCLUSION: An aconite cake-separated moxibustion treatment regimen of 3 treatments/wk and 1 cone/treatment appears to produce better therapeutic effects for D-IBS compared with the other tested regimens.展开更多
基金Supported by National Basic Research Program of China(973 Program),No.2009CB522900,2009CB522901Shanghai Top Clinical Medical Center of Acupuncture,Moxibustion and TuinaNational Natural Sciences Foundation of China,Nos.81303031 and 81202752
文摘AIM: To identify an appropriate therapeutic regimen for using aconite cake-separated moxibustion to treat diarrhea-predominant irritable bowel syndrome(D-IBS).METHODS: A factorial design was employed to examine the two factors of moxibustion frequency and number of cones. The two tested frequencies were three or six moxibustion sessions per week, and the two tested doses were one or two cones per treatment. A total of 166 D-IBS patients were randomly divided into four treatment groups, which included each combination of the examined frequencies and doses. The bilateral Tianshu acupoints(ST25) and the Qihai acupoint(RN6) were selected for aconite cake-separated moxibustion. Each patient received two courses of treatment, and each course had a duration of 2 wk. For each group, the scores on the Birmingham irritable bowel syndrome(IBS) symptom questionnaire, the IBS Quality of Life scale, the Self-Rating Depression Scale(SDS), the Self-Rating Anxiety Scale(SAS), the Hamilton Depression(HAMD) scale, and the Hamilton Anxiety(HAMA) scale were determined before treatment, after the first course of treatment, and after the second course of treatment. RESULTS: The symptom, quality of life, SDS, SAS, HAMD, and HAMA scores of the patients in all 4 aconite cake-separated moxibustion groups were significantly lower after the first and second courses of treatment than before treatment(P < 0.001 for all). The symptom, quality of life, SDS, SAS, HAMD, and HAMA scores of the patients in all four aconite cake-separated moxibustion groups were significantly lower after the second course of treatment than after the first course of treatment(P < 0.001 for all). Between-group comparisons after the second course of treatment revealed that the symptom scores for group 1(1 cone, 3 treatments/wk) and group 3(2 cones, 3 treatments/wk) were significantly lower than that for group 2(1 cone, 6 treatments/wk)(5.55 ± 5.05 vs 10.45 ± 6.61, P < 0.001; 5.65 ± 4.00 vs 10.45 ± 6.61, P < 0.001). Regarding the two levels of the two examined factors for aconite cake-separated moxibustion, after the first course of treatment, the changes in HAMA scores weresignificantly different for the two tested moxibustion frequencies(P = 0.011), with greater changes for the "6 treatments/wk" groups than for the "3 treatments/wk" groups; in addition, there were interaction effects between the number of cones and moxibustion frequency(P = 0.028). After the second course of treatment, changes in symptom scores for the 2 tested moxibustion frequencies were significantly different(P = 0.002), with greater changes for the "3 treatments/wk" groups than for the "6 treatments/wk" groups.CONCLUSION: An aconite cake-separated moxibustion treatment regimen of 3 treatments/wk and 1 cone/treatment appears to produce better therapeutic effects for D-IBS compared with the other tested regimens.
